Related Experiment Video
Updated: Mar 4, 2026
Assessment of Gut Barrier Integrity in Mice Using Fluorescein-Isothiocyanate-Labeled Dextran
Published on: November 18, 2022
Fistula Calprotectin as a Biomarker of Local Inflammation and Treatment Response in Perianal Fistulizing Crohn's
Runqi Wang1, Yanglong Wu1, Dongbo Xu2
1Department of Gastrointestinal Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Background:
Accurate assessment of tract-specific inflammatory activity remains difficult in perianal fistulizing Crohn's disease (pfCD), as current clinical and imaging indices incompletely reflect local activity.
Aims:
To evaluate fistula calprotectin (FiCP) as a tract-specific biomarker, focusing on diagnostic accuracy, associations with histological, clinical, and radiological indices, longitudinal responsiveness, and local infliximab exposure.
Methods:
In this single-center observational study (April 2023-July 2025; n = 105), patients with pfCD provided fistula exudate samples during surgical or outpatient assessment. FiCP concentrations were quantified by ELISA and correlated with histological inflammation, the Perianal Disease Activity Index (PDAI), the MRI-based modified Van Assche Index (mVAI), and total fistula volume (TFV). Diagnostic performance was analysed using receiver operating characteristic (ROC) curves with DeLong comparison, and treatment responsiveness was evaluated longitudinally using the standardised response mean (SRM). Serum and local infliximab concentrations were measured using ELISA.
Results:
FiCP levels were significantly higher in fistulas with severe versus mild histological inflammation (p = 0.021) and in clinically or radiologically active tracts (both p < 0.001). FiCP correlated with PDAI (R = 0.61), mVAI (R = 0.40), and local infliximab concentration (R = -0.64). FiCP discriminated active from quiescent fistulas (AUC 0.843; 95% CI 0.758-0.928) and retained diagnostic value in patients with normal CDAI scores. FiCP levels declined significantly after therapy and showed greater responsiveness than PDAI and TFV.
Conclusions:
FiCP represents a minimally invasive, tract-specific biomarker that mirrors local inflammatory activity and dynamically tracks treatment response in pfCD. Multicenter validation is warranted to define its clinical utility.
More Related Videos
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
07:32An Intravital Microscopy-Based Approach to Assess Intestinal Permeability and Epithelial Cell Shedding Performance
Published on: December 3, 2020
Related Concept Videos
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...